Capsaicin Regulates Glucose Metabolism in Rats Fed with Dietary Fiber by Regulating Microbiota-Short Chain Fatty Acids

TING GONG, HAIZHU WANG, JINCAN LEI, LINGQUN JIANG1 AND MING YUAN1*

Department of Pharmacy, Chongqing City Management College, 1Department of Medicine, Chongqing Medical and Pharmaceutical College, Chongqing 401331, China

Gong et al.: Capsaicin Regulates Glucose Metabolism in Rats Fed with Dietary Fiber

Capsaicin and dietary fiber are effective natural food ingredients to control the obesity and metabolic diseases. The aim of the present study was to investigate the improved anti-obesity effects by adding capsaicin to a high-fiber diet. Sprague–Dawley rats were fed with high fiber diet, and different doses of capsaicin. Plasma parameters, gut microbiota, bile acid and short-chain fatty acids were analyzed to detect the improved effects and possible mechanisms. The results showed that the addition of capsaicin further decreased the fasting blood glucose and insulin, and increased beta-muricholic acid, deoxycholic acid, chenodeoxycholic acid, and 3 beta-ursodeoxycholic acid when compared to only high fiber diet. Administration of 0.05 g/kg capsaicin showed the highest of tauro-alpha-muricholic acid sodium salt and tauro-beta-muricholic acid sodium salt and 0.1 g/kg capsaicin resulted in the highest of lithocholic acid, cholic acid and hyodeoxycholic acid. Capsaicin increased the abundance of microorganisms including Akkermansia, Allobaculum et al. and increased the short-chain fatty acids, especially acetic acid and butyric acid. Results from our study indicated that the addition of capsaicin have better effects to reduce the weight, insulin and fasting blood glucose, and the possibly mechanism can be due to the changes in bile acid composition, microbial abundance and short-chain fatty acids.

Key words: Dietary fiber, capsaicin, bile acid, gut microbiota, short-chain fatty acids

There is an emerging health concern worldwide on overweight or obese due to their close relationship with several diseases, including cardiovascular disease, type 2 diabetes mellitus and various forms of cancer[1]. Although there are a number of antiobesity drugs available, diet-control interventions still remain to be the preferred therapy for the management of obesity. Numerous studies have confirmed that the supplementation with natural functional food may help reduce the risk of obesity-related complications[2,3]. Dietary fiber is one of the functional ingredients which has beneficial effects on obesity-related metabolic diseases. Inulin is a soluble dietary fiber in fructan family extracted from chicory roots. It is considered to be a prebiotic that cannot be hydrolyzed by digestive enzymes in the human small intestine but can be fermented by probiotics[4]. Thus, it can modulate the composition and metabolic activity of the intestinal microbiota, which might potentially enhance the health of the host organism[5,6]. Some studies have demonstrated that early inulin intervention in High Dietary (HD) fed mouse can reduce the glucose metabolism disorders and gut dysbiosis in the offspring[7]. In addition, dietary fiber can be fermented by gut microbes into Short-Chain Fatty Acids (SCFAs), which have beneficial effects on the gut barrier and can mitigate obesity by regulating the endocrine activity[8]. Butyrate, in particular, is a key promoter of colon health and integrity, and can meet 60 %–70 % of the energy requirements necessary for colon cell proliferation and differentiation[9]. Therefore, it is becoming more and more popular to adjust the obesity and abnormal glucose and lipid metabolism by eating dietary fiber.

*Address for correspondence
E-mail: qtx2015630@163.com

Accepted 25 July 2023
Revised 05 October 2022
Received 18 December 2021
Indian J Pharm Sci 2023;85(4):1099-1109

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
Capsaicin (CAP) is a key ingredient in natural chili peppers. It has recently attracted considerable attention due to its positive role on gut flora by eliminating the disease-causing enteric pathogens, and promoting the growth of beneficial bacteria\cite{10,11}. There are several reports on the antimicrobial and anti-dysbiosis property of CAP by mediating the beneficial alteration of microbiota many studies also found that CAP can prevent the onset or development of diseases like obesity, diabetes, or inflammatory bowel diseases\cite{7,12}. For example, Baboota et al.\cite{13} reported that the oral administration of CAP can increase the weight loss of High Fat Diet (HFD) fed mice, and the changes in gut microbiota compositions was an important factor. CAP can also increase the bile acid content and glucose metabolism\cite{14}.

Therefore, both CAP and dietary fiber are effective natural food ingredients to control the obesity and metabolic diseases, it is worthwhile to study whether there are enhanced effects on obesity by the combination of CAP and dietary fiber. But most of the existing studies are conducted with HFD and type 2 diabetes models; the role of CAP in High fiber diets (HB) is rarely studied. The present study was conducted to explore the improved anti-obesity effects by the addition of CAP to HB, and to explore the possible mechanism of CAP by investigating the intestinal microbiota homeostasis in Sprague–Dawley (SD) rats.

**MATERIALS AND METHODS**

**Materials:**

CAP (≥95 %) was purchased from Henan Bis-Biotech co., Ltd. Sprague-Dawley (SD) rats were provided by Hunan SJA laboratory animal Co., Ltd. Inulin (≥90 %) was purchased from Henan Wanbang industrial co., Ltd.

**Animals and treatments:**

Animal experiments were conducted with SD rats. The experimental protocols were approved by the Institutional Animal Care and Use Committee of Southwest University (IACUC-20201008-01). Rats (200±20 g) were housed in individual stainless steel cages at 25°±1°, with relatively humidity of 40 %–70 %, and artificially illuminated with fluorescent lamps in 12 h light/dark cycles. Before the experiment, the rats were provided free access to water and diet for 1 w, and then randomly divided into four groups; Negative Control (NC), HB, high fiber diet with medium dose (0.01 %) of CAP (HBM), and high fiber diet with low dose (0.005 %) of CAP (HBL). The ingredient composition of experimental group diets was shown in Table 1. The high fiber feed contained 10 % inulin supplement based on the U.S. Standard AIN-93 feed formula\cite{15}.

**Sample collection:**

The animal mortality and signs of toxicity were observed once a day throughout the trial duration. Body weight and food consumption were recorded once a week. After feeding for 4 w, SD rats were euthanized to collect blood, the cecal content, and small intestine content, and the contents were put into the sterile doffer tubes and immediately frozen in liquid nitrogen for 30 s and then stored at −80° for a further use. All the operations were performed under aseptic conditions.

**TABLE 1: THE INGREDIENT COMPOSITIONS OF THE EXPERIMENTAL DIETS (g/kg DIET)**

<table>
<thead>
<tr>
<th></th>
<th>NC</th>
<th>HB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corn starch</td>
<td>549.5</td>
<td>449.5</td>
</tr>
<tr>
<td>Inulin</td>
<td>0</td>
<td>100</td>
</tr>
<tr>
<td>Soybean oil</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>a AIN-76 mineral mixture (% mixture)</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>Casein</td>
<td>200</td>
<td>200</td>
</tr>
<tr>
<td>b AIN-76 vitamin mixture (% mixture)</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Sucrose</td>
<td>100</td>
<td>100</td>
</tr>
<tr>
<td>L-cystine</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Cellulose</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Choline chloride</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>10</td>
<td>10</td>
</tr>
</tbody>
</table>
Biochemical analysis:

Plasma Triglyceride (TG) and Total Cholesterol (TC) concentrations were determined using commercially available kits (BioSino, Beijing, China). Fasting blood glucose, High Density Lipoprotein-Cholesterol (HDL-C) and Low-Density Lipoprotein Cholesterol (LDL-C) were determined using automatic biochemical analyzer (URIT-8021A). Plasma insulin concentration was measured using a mouse insulin Enzyme Linked Immunosorbent Assay (ELISA) kit (Jiancheng, Nanjing, China).

Gut microbiota analysis by 16S Ribosomal Ribonucleic Acid (16S rRNA) gene sequencing:

Deoxyribonucleic Acid (DNA) preparation, Polymerase Chain Reaction (PCR) amplification, and pyrosequencing were performed as described by Li et al. Briefly, total DNA was extracted from 250 mg of cecal contents using E.Z.N.A. Stool DNA kit (OMEGA, Bio-Tek, United States of America (USA)). A primer set (515F/926R) was used to amplify the V4 region of the 16S rRNA gene to analyze the gut microbiota. Each sample was amplified in triplicate with a reaction volume of 20 μl containing 1× Ex Taq™ PCR buffer, 10 pM each primer, 1.25 U TaKaRa Ex Taq (TaKaRa Biotechnology Co., Ltd., Dalian, China), and 5 ng genomic DNA was amplified using the following program; 5 min at 95°, followed by 30 cycles of 94° for 30 s, then 56° for 30 s, and 72° for 30 s, and finally, 10 min at 72°. PCR products were purified using the QIAEX II Gel Extraction Kit (QIAGEN). Library preparation and pyrosequencing were performed at the Chinese National Human Genome Center in Shanghai with 454 GS FLX sequencing platform (Roche). The raw sequences were available on the National Center for Biotechnology Information (NCBI)/European Bioinformatics Institute (EBI) /DNA Data Bank of Japan (DDBJ) Sequence Read Archive (Accession No. DRA002627 and DRA0012641). The average read length was 250 bp. By randomly sampling 30 681 sequences from each sample, the resulting sequences were rarefied separately, so that the sampling workload of the entire sample was equal. To predict the functional profiles of microbial communities, Operational Taxonomic Unit (OTU) analysis was conducted by clustering sequences at the 97 % similarity level (USEARCH, version 10.0), and 0.005 % of all sequences was used as the threshold to filter OTUs. For beta diversity, species diversity matrix was calculated by a variety of algorithms, such as binary Jaccard, Bray–Curtis, and unweighted UniFrac (only for bacteria). The Principal Coordinate Analysis (PCoA) results were plotted using R software.

Bile acid analysis:

Bile acid analysis by Ultra-High Performance Liquid Chromatography-Time of Flight/Mass Spectrometry (UHPLC-TOF/MS). 10 mg of small intestines contents was weighed and dissolved in 1000 µl methanol (-20), followed by vortexing for 60 s, and sonicating for 30 min. The supernatants were collected after centrifugation at 12 000 rpm at 4° for 10 min, and then diluted by fifty-fold. For chromatographic analysis, ACQUITY UPLC® BEH C18 (2.1×100 mm, 1.7 μm, Waters Corp.) was used as the column. The injection volume was 5 μl, the mobile phase solvents were 0.01 % formic acid (A) and acetonitrile (B). Flow rate was 0.25 ml/min. For Quadrupole-TOF (Q-TOF) MS conditions, Electrospray Ionization (ESI) positive and negative ion modes were used for detection. The ion source temperature was 500° and the voltage was ~4500 V. Nebulizing gas and auxiliary gas (nitrogen) were set at 50 psi, curtain gas was at 30 psi and collision gas at 6 psi. Lithocholic acid (LCA) and other 39 substance were used as the bile acid standards (Sigma, USA). The High Performance Liquid Chromatography (HPLC) chromatograms chromatogram of bile acid standards were presented in fig. 1 and the standard curves were provided in Table 2.

SCFAs quantification by Gas Chromatography (GC):

The SCFAs in the cecal contents were determined according to the method described by Zhang et al. Cecal contents (0.5 mg): 0.5 mg cecal contents were weighed and dissolved in 2 ml mixtures containing crotonic acid (5 mmol/l) and sodium hydroxide (10 mmol/l). The supernatants were collected after centrifugation at 10 000 rpm at 4° for 15 min. Quantification analysis of fecal SCFAs was undertaken as previously described using an Agilent 7890 A. The chromatographic conditions were set as; injection volume 1 μl, inlet temperature 220°, column flow 0.95 ml/min, column temperature 90°, equilibrium time 0.5 min, temperature increased to 150° by 5°/min, retention time 9 min, detector temperature 230°, hydrogen flow 40 ml/min, air flow 400 ml/min, and tail blowing flow 40 ml/min.
**Fig. 1:** Gas chromatogram of SCFAs in standard solution (20 mmol/l)

**TABLE 2: CALIBRATION CURVES OF DIFFERENT (BILE ACIDS) IN STANDARD SOLUTION**

<table>
<thead>
<tr>
<th>Bile acid</th>
<th>Full name</th>
<th>Retention time (min)</th>
<th>Linear equation</th>
<th>Correlation coefficient (R)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LCA</td>
<td>Lithocholic acid</td>
<td>32.49</td>
<td>Y=-1219.6+2452.7x</td>
<td>0.996509278</td>
</tr>
<tr>
<td>β-UDCA</td>
<td>3β-Ursodeoxycholic acid</td>
<td>20.61</td>
<td>Y=-826.9+8195.7x</td>
<td>0.997482682</td>
</tr>
<tr>
<td>DCA</td>
<td>Deoxycholic acid</td>
<td>27.88</td>
<td>Y=3170.5+6339.8x</td>
<td>0.998563291</td>
</tr>
<tr>
<td>CDCA</td>
<td>Chenodeoxycholic acid</td>
<td>27.3</td>
<td>Y=-1829.4+3711.6x</td>
<td>0.995607743</td>
</tr>
<tr>
<td>HDCA</td>
<td>Hyodeoxycholic acid</td>
<td>22.6</td>
<td>Y=299.04+3227x</td>
<td>0.997026219</td>
</tr>
<tr>
<td>α-MCA</td>
<td>α-Muricholic acid</td>
<td>15.84</td>
<td>Y=-108.95+4376.1x</td>
<td>0.995819998</td>
</tr>
<tr>
<td>UCA</td>
<td>Ursocholic acid</td>
<td>13.32</td>
<td>Y=-447.66+1843.2x</td>
<td>0.997831515</td>
</tr>
<tr>
<td>β-MCA</td>
<td>β-Muricholic acid</td>
<td>17.28</td>
<td>Y=132.52+1879.9x</td>
<td>0.996643952</td>
</tr>
<tr>
<td>CA</td>
<td>Cholic acid</td>
<td>21.65</td>
<td>Y=1176.8+2948.6x</td>
<td>0.999327695</td>
</tr>
<tr>
<td>TLCA</td>
<td>Taurolithocholic acid sodium salt</td>
<td>24.44</td>
<td>Y=-496.67+12631x</td>
<td>0.998144375</td>
</tr>
<tr>
<td>TDCA</td>
<td>Taurodeoxycholic acid sodium salt</td>
<td>18.92</td>
<td>Y=285.19+9813x</td>
<td>0.99745871</td>
</tr>
<tr>
<td>TCDCA</td>
<td>Taurochenodeoxycholic acid</td>
<td>17.56</td>
<td>Y=-296.28+8556.7x</td>
<td>0.998502153</td>
</tr>
<tr>
<td>TCA</td>
<td>Taurocholic acid sodium salt</td>
<td>12.96</td>
<td>Y=-68.605+4988.1x</td>
<td>0.999233726</td>
</tr>
<tr>
<td>T-α-MCA</td>
<td>Tauro-α-muricholic acid sodium salt</td>
<td>7.391</td>
<td>Y=305.65+8644.9x</td>
<td>0.995792518</td>
</tr>
<tr>
<td>T-β-MCA</td>
<td>Tauro-β-muricholic acid sodium salt</td>
<td>7.662</td>
<td>Y=27.883+7597x</td>
<td>0.99666197</td>
</tr>
</tbody>
</table>
The retention time of each chromatographic peak was used for qualitative analysis, and the peak area was used for quantification. GC chromatogram of SCFAs standard was shown in fig. 2 and the standard curves were provided in Table 3.

Metabolite analysis by LC-MS/MS:

A 100 mg sample of cecal contents was weighed and mixed thoroughly into 800 μl of acetonitrile/methanol (1:1, w/v). The mixture was incubated for 60 min at -20°, then centrifuged at 16 000 rpm and 4° for 20 min. The upper phase was collected and vacuum dried, then dissolved in 100 μl acetonitrile:water (1:1, w/v) for analysis.

Pretreated cecal content samples were analyzed using an Agilent 1290 Infinity LC system (Agilent, USA) coupled with a Pegasus HT TOF mass spectrometer (LECO, USA). An ACQUITY UPLC BEH Amide 1.7 μm, 2.1 mm×100 mm column was used to separate the derivatives. The injection volume was set at 5 μl, and column temperature was set to 25°. The flow rate was 0.3 ml/min. Chromatographic mobile phase A was water+25mM ammonium acetate+25 mM ammonia water, while phase B was acetonitrile.

Mass spectra were acquired under the following settings; ion source gas 1 (Gas1) was 60, ion source gas 1 was 60, ion source gas 2 was 60, curtain gas was 30, source temperature was 600°. Ion Sapary Voltage Floating (ISVF): ±5500 V, TOF MS scan m/z range was 60-1200 Da, product ion scan m/z range was 25-1200 Da, TOF/MS scan accumulation time was 0.15 s/spectra, product ion scan accumulation time was 0.03 s/spectra, secondary MS has information dependent acquisition, Declustering Potential (DP) was ±60 V, collision energy was 30 Ev. Isotopes within 4 Da were excluded, and six candidate ions were monitored per cycle.

LC-TOF/MS raw data were first analyzed by MS-DIAL software with the Xtensible Computational MS (XCMS) database, including raw peak extraction, data baseline filtering and calibration, peak alignment, deconvolution analysis, peak identification and peak area integration. Subsequently, normalized data were input to the SIMCA 14.1 software package (Umetrics AB, Umea, Sweden). After mean centralizing and unit variance scaling, multivariate analyses, such as Principal Component Analysis (PCA) and Orthogonal Partial Least Squares Discriminant Analysis (OPLS-DA), were performed to visualize metabolic differences between the four groups. Finally, differentially expressed metabolites were identified and characterized by searching the online Kyoto Encyclopedia of Genes and Genomes (KEGG, http://www.genome.jp/kegg/).

<table>
<thead>
<tr>
<th>SCFAs</th>
<th>Linear equation</th>
<th>Correlation coefficient (R²)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetic acid</td>
<td>y=62.58x-795.68</td>
<td>0.9914</td>
</tr>
<tr>
<td>Propionic acid</td>
<td>y=121.56x-1144.4</td>
<td>0.9963</td>
</tr>
<tr>
<td>i-butyric acid</td>
<td>y=171.47x-942.01</td>
<td>0.9988</td>
</tr>
<tr>
<td>n-butyric acid</td>
<td>y=171.6x-1250.1</td>
<td>0.998</td>
</tr>
<tr>
<td>i-valeric acid</td>
<td>y=193.82x-893.63</td>
<td>0.9996</td>
</tr>
<tr>
<td>n-valeric acid</td>
<td>y=204.8x-843.75</td>
<td>0.9997</td>
</tr>
</tbody>
</table>

Fig. 2: HPLC chromatogram of bile acids in standard solution
Statistical analysis:

All data were expressed as mean and standard deviation (n=8). Data were subjected to one-way analysis of variance using Origin 8.5 and Statistical Package for the Social Sciences (SPSS) version 20.0. The differences among groups were examined by Duncan’s multiple-range test. p<0.05 was considered to be statistically significant.

RESULTS AND DISCUSSION

After feeding for 4 w, the weight gain of SD rats was shown in fig. 3A. Compared to the NC group, the weight gain in HB, HBL and HBM groups were significant decreased, especially in HBM and HBL groups. It is well known that dietary fiber has positive effects on body weight loss, which is accord with our research. The data of food intake in fig. 3B showed that the rats in HBL and HBM groups recorded much lower food intake than that in NC and HB groups after 2 w of feeding.

The effects of CAP on blood biochemical parameters of rats fed with different diets were shown in Table 3. There were no significant differences among the treatment groups in plasma TG, TC, LDL-C and HDL-C. However, for the insulin content, it was significantly decreased in rats fed with CAP (HBL and HBM groups), when compared with HB. HBM group showed the lowest fasting blood, but only a slight decrease in fasting blood was detected in HBL group with comparison to HB group.

In order to understand the effects of CAP on the intestinal microflora profile of SD rats fed with dietary fiber, fecal samples were harvested at the 4th w of the experiment, the V3 and V4 16S rRNA variable gene regions in the fecal samples were sequenced using the Illumina MiSeq platform. We characterized 633 OTUs from 36549 high-quality sequences. The PCA was performed based on OUTs and presented in fig. 4A, which showed the similarities and differences among different samples. The NC group was notably separated from HB group, a clear separation was observed among the HB and HBL, HBM, suggesting that the gut microbiota was substantially changed by CAP treatment. Fig. 4B exhibited the Bray–Curtis distances on the beta (β)-diversity of gut microbiota in rats with different diets. It can be seen that there were only slight differences in β-diversity of gut microbiota among the HB, HBL and HBM groups. But Shannon index in fig. 4C showed significant differences between HBL and HB groups. Results of both alpha and PCA analyses indicated that the intestinal flora of SD rats treated by CAP were significantly changed. The histogram of community structure at the genus level of intestinal flora was shown in fig. 4D, and the top 20 most dominant genera were shown in fig. 4E. Compared with HB group, CAP-fed groups decreased the Ruminococcaceae uncultured and Ruminococcus gnavus group but increased the Faecalibaculum. Similar concentration in Akkermansia was found in HB, HBL and HBM groups, but it was higher than NC group. And a significant lower concentration in bacteroidales_S24–7 was observed in HBM group than HB group.

![Fig. 3](image-url)
Bile acids are synthesized in the liver from cholesterol and released into the intestine to help the digestion of dietary lipids. To determine whether the weight loss in the CAP-treated groups was associated with the changes in bile acids, the composition and content of 15 bile acids species in small intestine were assayed, and the results were shown in fig. 5. Compared with HB and NC, the unconjugated bile acids including Beta-Muricholic acid (β-MCA), Deoxycholic acid (DCA), Chenodeoxycholic acid (CDCA), and β-Ursodeoxycholic acid (β-UDCA) were significantly increased in CAP fed rats (HBL and HBM groups). And higher LCA, Cholic acid (CA) and Hyodeoxycholic acid (HDCA) were observed in HBM than that in HB (fig. 5A and fig. 5B). Besides, compared with NC, the Ursocholic Acid (UCA) and LCA were significant decreased in HBL, HBM, and HB (fig. 5A and fig. 5B). CAP-fed rats (HBL and HBM) also showed lower conjugated Bile Acids and Taurochenodeoxycholic Acid (TCDA) than only fiber-fed rats (HB) (fig. 5C). Higher Ta-MCA and Tβ-MCA were found in HBL (fig. 5C). And HBM showed lower Taurocholic acid (TCA) sodium salt than HB (fig. 5C).

A Pearson correlation analysis was conducted to link the gut microbiota genera and bile acid profiles, and the heatmap of Pearson correlation analysis was presented in (fig. 5D). The results showed that Allobaculum was positively correlated with Alpha-Muricholic acid (α-MCA). Akkermansia was negatively correlated with LCA and positively associated with Taurolithocholic acid Sodium Salt Taurolithocholic acid (TLCA) sodium salt and DCA. Lactobacillus was negatively correlated with TLCA. Bacteroides was negatively correlated DCA and α-MCA.
SCFAs are the final products of dietary fibers and resistant starch through microbial fermentation, and they play an important role in the prevention and treatment of obesity[18]. Acetic, propionic and butyric acids can serve as an energy source to human intestine epithelium[19]. The fecal SCFA excretion in SD rats fed with different diets were shown in Table 4. The highest acetic acid, butyric acid, i-butyric acid and total SCFAs were found in HBM. No significant differences were found in propionic acid, i-valeric acid, and n-valeric acid in CAP groups.

The aim of this work was to study the impact of the CAP on gut microbes and metabolites in SD rats fed with dietary fiber. The results showed that CAP can significantly reduce the food intake and body weight gain of the rats fed with fiber diet. Bile acids, intestinal flora and metabolites were determined in order to investigate whether the weight loss was caused by reduced feed intake or by some other changes. Many studies have proven that dietary fiber can regulate the metabolism of human body[20]. In our study, the addition of CAP to dietary fiber can further reduce the insulin levels, especially with the addition of 0.1 mg/kg CAP. At the same time, the combination of CAP and fiber was more effective on reducing fasting blood glucose. These results indicated that the addition of CAP in dietary fiber has a more regulatory effect on glucose metabolism.

Bile acids, derived from cholesterol in the liver, are an important compound in the gut lumen in response to ingestion of dietary fat. In the lower gastrointestinal tract, primary bile acids are converted to secondary bile acids through microbial metabolism, and secondary bile acids are positively associated with chronic disease, e.g., liver disease and colorectal cancer[21,22]. Both primary and secondary bile acids are strong signaling molecules in fat metabolism. In the liver, intestine, and other tissues, bile acids are also strong signaling molecules activating Farnesoid-X Receptor (FXR) and G-Protein-Coupled Bile Acid Receptor (GPBAR1/TGR5), and bile acids can help to regulate the several systemic endocrine functions, including lipid and glucose metabolism, immune responses, and energy metabolism[23,24].

![Fig. 5: (A and B): Unconjugated bile acids of SD rats fed with CAP in fiber diet; (C): Conjugated bile acids of SD rats fed with CAP in fiber diet. Values are mean±SEM (n=8). Data were analyzed using one-way ANOVA with multiple comparisons. Different letters denote significant differences (p<0.05) and (D): Pearson correlation heat map between key gut microbial taxa and BA profiles. Data are expressed as the mean±SEM. One-way ANOVA with Bonferroni post hoc test. Note: ( ): NC; ( ): HB; ( ): HBL and ( ): HBM]
The most potent ligands for FXR are CDCA, DCA, LCA, CA, Glycocholic acid (GCA) and β-MCA\cite{25}, among which CDCA has the greatest potency, followed by DCA, LCA, and finally CA\cite{23}. Conversely, TGR5 is mainly activated by the secondary bile acids, LCA and TLCA\cite{23}, and it is predominantly expressed in the enteric nervous system and influences distal gut motility\cite{26,27}. Furthermore, bile acids are harmful when at higher concentrations, particularly those with higher hydrophobicity\cite{28}. Therefore, changes in the composition of the bile acid pool may impact the health-related outcomes. In our research, the addition of CAP significantly increased CDCA, DCA, CA, and β-MCA contents (fig. 5A), indicating that CAP may activate the FXR signaling pathway via bile acid metabolism. Moreover, the activation of FXR is involved in lipid, glucose, and drug metabolism\cite{29}, inflammation\cite{30}, as well as epithelial cell proliferation\cite{31}. This may be one reason for the changes of insulin and fasting blood glucose caused by CAP. LCA was increased significantly in medium dose of CAP, yet TLCA was decreased. Further researches were required to study the influences of CAP on distal gut motility.

The changes of gut bile acid levels are usually associated with bacterial growth and inflammation\cite{32}. In the proximal small intestine, bile acids can protect gut mucosa against pathogens due to their amphipathic property and solubilizing ability. In the distal small intestine, this protection can be mediated by increased synthesis and secretion of antimicrobial factors from intestinal epithelium by gene induction through interaction with FXR\cite{33}. Therefore, the composition of bile acids directly affects the changes of intestinal microorganisms.

*Akkermansia* was negatively correlated with FXR agonists LCA and positively associated with TLCA and DCA. Tauro-Beta-Muricholic Acid (Tβ-MCA) is a powerful (gut microbiota-sensitive) FXR antagonist in mice\cite{34}. Some studies have shown that *Lactobacillus* is negatively correlated with FXR antagonists (MCA)\cite{35} and positively associated with FXR agonists, such as TCA. Our results showed a similar trend, but only slight differences were observed (fig. 5D), probably due to the small sample size. In addition, *Lactobacillus* was negatively correlated with TLCA. And *Bacteroides* was negatively correlated DCA and α-MCA.

The gut microbiota is a collection of archaea, bacteria, and eukarya that have evolved over thousands of years to form a symbiotic relationship with human hosts\cite{36}. These microbial populations influence metabolic, immune and defense systems in the intestine and consequently, human health\cite{19,37}. In our research, at the species level, CAP reduced the OTU assigned to the Bacteroidales S24-7, Ruminococcaceae un cultured, and *Ruminococcus gnavus* group, but enhanced *Faecalibaculum* and *Akkermansia*. *Akkermansia* is a mucin-degrader bacterium and has many beneficial effects such as anti-inflammatory properties\cite{38}, anti-obesity\cite{39,40}, mitigate inflammation, regulation of glucose metabolism\cite{41}, and has the ability to produce SCFAs\cite{42}. The increased *Akkermansia* suggested that CAP can reduce intestinal inflammation, improve glucose metabolism, and enhance weight loss in rats. Bacteroidales_S24-7 is a kind of carbohydrate-fermenting bacteria that produces SCFAs\cite{43}. It can degrade complex polysaccharides into acetate, propionate, and succinate\cite{44}. However, we did not find a decrease in acetic acid and propionic acid in our results, one of the possible reasons may be the action of other microorganisms that produced SCFAs. Compared with HB, acetic acid, butyric acid and total SCFAs was significantly increased in HBM (Table 5), which may be caused by the increase in some microbes, such as *Akkermansia, Allobaculum et al. Allobaculum* is a beneficial intestinal bacterium that produces lactic, butyric acids and small amounts of ethanol from glucose\cite{45,46}, resulting in the decrease of glucose digestion. Medium dose of CAP increased the *Allobaculum*, leading to the differences in SCFAs content.

### TABLE 4: EFFECTS OF CAP ON PLASMA PARAMETERS IN SD RATS (n=8)

<table>
<thead>
<tr>
<th></th>
<th>NC</th>
<th>HB</th>
<th>HBL</th>
<th>HBM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasma TC (mmol/l)</td>
<td>3.07±0.353a</td>
<td>3.19±0.198a</td>
<td>3.00±0.014a</td>
<td>3.23±0.269a</td>
</tr>
<tr>
<td>Plasma TG (mmol/l)</td>
<td>0.66±0.007a</td>
<td>0.56±0.0283a</td>
<td>0.68±0.120a</td>
<td>0.58±0.148a</td>
</tr>
<tr>
<td>LDL-C (mmol/l)</td>
<td>1.29±0.297a</td>
<td>1.39±0.049a</td>
<td>1.19±0.184a</td>
<td>1.34±0.035a</td>
</tr>
<tr>
<td>HDL-C (mmol/l)</td>
<td>1.28±0.113a</td>
<td>1.66±0.459a</td>
<td>1.31±0.396a</td>
<td>1.40±0.120a</td>
</tr>
<tr>
<td>Insulin (mU/l)</td>
<td>50.26±5.742a</td>
<td>49.87±0.007a</td>
<td>35.47±1.273c</td>
<td>36.82±4.200a</td>
</tr>
<tr>
<td>Fasting blood glucose (mmol/l)</td>
<td>4.82±0.064a</td>
<td>4.41±0.318b</td>
<td>3.97±0.014bc</td>
<td>3.71±0.120c</td>
</tr>
</tbody>
</table>

Note: Different letters in the same row indicate statistical difference (p<0.05)
It is well known that SCFAs suppress inflammation, regulate the gut bacterial ecology\cite{47}, and glucose and lipid metabolism. Inulin, the main component of HD fiber feed in our study, was found to be able to generate the short chain free fatty acids\cite{48}, and with the addition of CAP, the concentration of SCFAs significantly increased, especially in the 0.1 g/kg group. Therefore, the loss of body weight may be the result of the combined action of reduced feed intake and changes in intestinal flora.

Dietary fiber and CAP are promising ingredients for preventing obesity and related metabolic disorders\cite{8,14}. Our research used these two elements together and found that the addition of CAP in dietary fiber enhanced the regulation of glucose metabolism and body weight. The possible mechanism can be related to the regulation on the composition of bile acids and gut microbiome. The changes in the abundance of some microbes, such as Akkermansia, Allobaculum, increased the content of SCFAs, and then modulated the weight gain and glucose metabolism; however, elucidation of the detailed mechanism requires further experiments.

Acknowledgement:

This research was supported by National Natural Science Foundation of Chongqing (cste2019jcymxmx0439) and Scientific and Technological Research Program of Chongqing Municipal Education Commission (KJ1726396).

Author’s contributions:

Ting Gong and Haizhu Wang have contributed equally to this work.

Conflict of interests:

The authors declared no conflict of interests.

### REFERENCES